

News Release

Your Contact

Media Relations

markus.talanow@emdgroup.com

Phone: +49 6151 72-7144

Investor Relations

investor.relations@emdgroup.com

Phone: +49 6151 72-3321

July 1, 2019

Merck KGaA, Darmstadt, Germany, Places Bonds Amounting to € 2 Billion

- **Issuance is final key component in the financing of the planned Versum transaction**
- **Three tranches placed**
- **Bonds significantly oversubscribed**

Darmstadt, Germany, July 1, 2019 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today successfully placed bonds amounting to € 2.0 billion. The placement is a component of the financing of the planned acquisition of Versum Materials Inc. (NYSE: VSM), which was announced in April 2019.

The placement comprises three tranches: a fixed-rate bond with a maturity of four and a half years amounting to € 600 million and paying a coupon of 0.005%, a second tranche of € 600 million with a maturity of 8 years, paying a coupon of 0.375% as well as a third tranche of € 800 million with a maturity of 12 years, paying a coupon of 0.875%. On June 18, Merck KGaA, Darmstadt, Germany, had already placed a euro hybrid bond amounting to € 1.5 billion to finance the planned acquisition.

“Following the successful placement of hybrid bonds two weeks ago, we have made use of the favorable market environment in order to finalize the financing of the planned acquisition of Versum. We’re resolutely pursuing our conservative financial



News Release

policy further,” said Marcus Kuhnert, Member of the Executive Board and Chief Financial Officer of Merck KGaA, Darmstadt, Germany.

The bonds issued today were significantly oversubscribed and achieved a well-diversified distribution among a wide range of institutional investors such as fund managers, insurance companies, pension funds, and banks. Bookrunners of the transaction were the Group’s relationship banks.

The acquisition of Versum is expected to strengthen the Performance Materials business sector. Versum is a leading supplier of innovation-driven, high-purity process chemicals, gases and equipment for semiconductor manufacturing. The transaction is expected to close in the second half of 2019, subject to regulatory clearances and the satisfaction of other customary closing conditions.

Merck KGaA, Darmstadt, Germany, is rated “A” (stable outlook) by Standard & Poor’s, “A-” (stable outlook) by Scope and “Baa1” (stable outlook) by Moody’s (details available [here](#)).

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.